Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2016
Dec 2016 | Download as pdf

Soluble Therapeutics Acquired by CytoBioscience more

Nov 2016 | Download as pdf

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Nov 2016 | Download as pdf

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

Nov 2016 | Download as pdf

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Nov 2016 | Download as pdf

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

Nov 2016 | Download as pdf

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

Nov 2016 | Download as pdf

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Nov 2016 | Download as pdf

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Nov 2016 | Download as pdf

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

Nov 2016 | Download as pdf

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

HOUSTON, Nov. 1, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been treated in a multicenter Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with recurrent glioblastoma.

The CAPTIVE trial is evaluating the potential effect of DNX-2401 and KEYTRUDA in patients with recurrent glioblastoma, a disease for which there is neither a cure nor adequate treatment. Leading medical centers inthe United States and Canada are participating.

DNX-2401 is a potent conditionally replicative oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response.

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.  This activity enhances the T cell response and leads to effective tumor destruction. KEYTRUDA is currently approved in the United States for advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and advanced head and neck squamous cell cancer (HNSCC).

"Glioblastoma is a difficult disease to treat with conventional therapies," said Frank Tufaro, Ph.D., Chief Executive Officer of DNAtrix. "Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease."

For more information about the CAPTIVE trial, visit the website ClinicalTrials.gov and search for the identifier NCT02798406.

About DNX-2401
DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer, with glioblastoma as the initial indication. Glioblastoma is the most aggressive form of brain cancer, which has a median survival of 15 months following a patient's initial diagnosis. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process can also trigger an anti-tumor immune response. DNX-2401 is currently being investigated in several clinical studies and has been well tolerated in all settings. Compelling results from clinical studies in recurrent glioblastoma indicate that DNX-2401 can (1) replicate in human brain tumors for a period of weeks to months, (2) trigger immune cell infiltration into the tumor, (3) cause ongoing tumor destruction and (4) induce durable responses to therapy. In these studies, patient survival has been prolonged, including in those achieving a complete response.

About DNAtrix
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.DNAtrix.com.

Contact:                
DNAtrix 
Imran Alibhai, Ph.D. 
SVP Business Development 
ialibhai@dnatrix.com

Source: http://www.prnewswire.com/news-releases/ back

Oct 2016 | Download as pdf

Robotics: Germ-Zappers Are Saving Lives more

Oct 2016 | Download as pdf

DHR first in RGV with xenon UV disinfection systems more

Oct 2016 | Download as pdf

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Oct 2016 | Download as pdf

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Oct 2016 | Download as pdf

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Oct 2016 | Download as pdf

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Oct 2016 | Download as pdf

Cardiovate Develops First Bioabsorbable Vascular Graft more

Oct 2016 | Download as pdf

Funding San Antonio’s Biotech Ecosystem more

Oct 2016 | Download as pdf

A biotech groups to share in major military contract to manufacture stem cells more

Sept 2016 | Download as pdf

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Sept 2016 | Download as pdf

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Sept 2016 | Download as pdf

Robots show Marin, Sonoma hospitals the light on disinfection more

Sept 2016 | Download as pdf

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Sept 2016 | Download as pdf

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

Sept 2016 | Download as pdf

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Aug 2016 | Download as pdf

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Aug 2016 | Download as pdf

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Aug 2016 | Download as pdf

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Aug 2016 | Download as pdf

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

Aug 2016 | Download as pdf

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

Aug 2016 | Download as pdf

SA biotech firm drawing global interest year after moving from Germany more

Aug 2016 | Download as pdf

TFS Corporation makes bond offer more

Aug 2016 | Download as pdf

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

Aug 2016 | Download as pdf

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

Aug 2016 | Download as pdf

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

Aug 2016 | Download as pdf

TFS Corporation - July 2016 Update more

Aug 2016 | Download as pdf

StemBioSys reaches European distribution agreement for its products more

Aug 2016 | Download as pdf

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

July 2016 | Download as pdf

DNAtrix Receives European Medicines Agency PRIME Designation more

July 2016 | Download as pdf

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

July 2016 | Download as pdf

Australia forestry company TFS Corp gets two ratings upgrades more

July 2016 | Download as pdf

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

July 2016 | Download as pdf

StemBioSys reaches distribution agreement for its products in South Korea more

July 2016 | Download as pdf

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

June 2016 | Download as pdf

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

June 2016 | Download as pdf

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

June 2016 | Download as pdf

Texas among top states in foreign investments more

June 2016 | Download as pdf

How Your Family Drives Business Decisions more

June 2016 | Download as pdf

StemBioSys enters distribution agreement for its products in Japan more

May 2016 | Download as pdf

San Antonio biotech firm takes big step toward global expansion more

May 2016 | Download as pdf

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

May 2016 | Download as pdf

This hospital spent $300,000 on giant, superbug-killing robots more

May 2016 | Download as pdf

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

May 2016 | Download as pdf

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

May 2016 | Download as pdf

Bexar County added 4,350 jobs last year, study says more

April 2016 | Download as pdf

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

April 2016 | Download as pdf

San Antonio venture capital funding fell last year more

April 2016 | Download as pdf

neoSurgical Limited Expands Indications For neoClose Device more

April 2016 | Download as pdf

Bio2 Medical Closes Series D Preferred Stock more

April 2016 | Download as pdf

TFS undertakes $60 million placement more

April 2016 | Download as pdf

Bluegrass Vascular Technologies’ catheter system used on first patient more

March 2016 | Download as pdf

Cytocentrics refunds $100,000 in economic development funds to city more

March 2016 | Download as pdf

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

March 2016 | Download as pdf

Long-term acute care facility in California implements Xenex germ-zapping robot more

March 2016 | Download as pdf

Robotic housekeeper disinfects the rooms at Modesto hospital more

March 2016 | Download as pdf

Aerin Medical raises $16.7M, adds new board members more

March 2016 | Download as pdf

Brokers Sniff Sweet Potential In TFS Corp more

March 2016 | Download as pdf

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Feb 2016 | Download as pdf

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

Feb 2016 | Download as pdf

TFS Corporation - January 2016 Update more

Feb 2016 | Download as pdf

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Feb 2016 | Download as pdf

Strategic partnering deal with Cytocentrics more

Feb 2016 | Download as pdf

Cytocentrics CEO: San Antonio to get big boost from new deal more

Feb 2016 | Download as pdf

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Feb 2016 | Download as pdf

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Feb 2016 | Download as pdf

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Feb 2016 | Download as pdf

Santalis announces positive results for pediatric atopic dermatitis treatment more

Feb 2016 | Download as pdf

Here’s why the TFS Corporation Limited share price soared 28% today more

Jan 2016 | Download as pdf

Cytocentrics gaining traction in San Antonio more

Jan 2016 | Download as pdf

The Drugstore Acne Fighters Dermatologists Swear By more

Jan 2016 | Download as pdf

neoSurgical® Begins Postmarket Surveillance Study more

Jan 2016 | Download as pdf

Santalis Announces First Subject Enrolled in Phase 2 Trial more

Jan 2016 | Download as pdf

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Jan 2016 | Download as pdf

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more